期刊文献+

急性白血病hTERT mRNA和P16蛋白表达与端粒酶活性的关系 被引量:1

Relationship of the expression of hTERT mRNA and P16 protein with telomerase activity in acute leukemia
下载PDF
导出
摘要 目的 探讨端粒酶逆转录酶 (hTERT)和P16蛋白表达与端粒酶活性的关系及其在急性白血病发病过程中的作用。方法 采用TRAP和RT PCR法分别检测 4 0例急性白血病患者 (白血病组 )及 2 0例非白血病且骨髓正常者 (对照组 )的端粒酶活性与hTERTmRNA表达 ;用免疫组化SP法测定P16蛋白表达。结果 白血病组端粒酶活性和hTERTmRNA的阳性率分别为 75 %和 80 % ,而对照组均为阴性。白血病组hTERTmRNA表达与端粒酶活性呈显著正相关 (r =0 .6 5 ,P <0 .0 1)。白血病组及对照组P16蛋白阳性表达率分别为 35 %和 95 % ,两者比较差异有非常显著性意义 (P <0 .0 1)。白血病组P16蛋白表达与端粒酶活性呈显著负相关 (r =- 0 .81,P <0 .0 1)。结论 hTERTmR NA表达和 p16基因失活可能在急性白血病发病过程中起一定作用。急性白血病细胞端粒酶活性激活可能与hTERTmRNA表达及 p16基因失活有关。 Objective To study the expression of human telomerase reverse transcriptase (hTERT) and P16 protein and their relation with telomerase activity in the carcinogenesis of acute leukemia. Methods Telomerase activity and hTERTmRNA were detected in 40 patients with acute leukemia and 20 normal controls by TRAP and RT-PCR, respectively; P16 protein was examined by immunocytochemical method. Results The positive rates of telomerase activity and hTERTmRNA were 75% and 80% in 40 cases of acute leukemia, respectively, whereas neither hTERTmRNA nor telomerase activity was detected in normal controls. There was a significant correlation between the expression of hTERTmRNA and telomerase activity (r= 0.65, P< 0.01). It was found that P16 protein was 35% (14/40) in acute leukemia and 95% (19/20) in normal controls (P< 0.01). The expression of P16 protein was found to be inversely correlated with telomerase activity (r=- 0.81, P< 0.01). Conclusion The expression of hTERTmRNA and inactivation of p16 may play an important role in the carcinogenesis of acute leukemia.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2004年第3期269-270,278,共3页 Journal of Xi’an Jiaotong University(Medical Sciences)
关键词 急性白血病 端粒酶 基因表达 P16蛋白 acute leukemia telomerase gene expression P16 protein
  • 相关文献

参考文献15

  • 1Blackbum EH. Telomerase [J]. Ann Rev Biochem,1992,61(2):113-117.
  • 2Greider CW. Telomerase activity, cell proliferation,and cancer [J]. Proc Natl Acad Sci USA,1998,95(7):90-92.
  • 3Buys CH. Telomeres, telomerase, and cancer [J]. N Engl J Med, 2000, 342(17):1282-1283.
  • 4Jong HS, Park YI, Kim S, et al. Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis [J]. Cancer,1999,86(4):559-565.
  • 5He XS,Su Q,Chen ZC, et al. Expression deletion and mutation of p16 gene in human gastric cancer [J].World J Gastroenterol, 2001,7(4):515-521.
  • 6Takakura M, Kyo S, Kanaya T, et al. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer [J]. Cancer Res,1998, 58(7):1558-1561.
  • 7Nakano K, Watney E, Mc Dougall JK. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer [J]. Am J Pathol,1998,153(3):857-864.
  • 8Broccoli D, Young JW, de Lange T, et al. Telomerase activity in normal and malignant hematopoietic cells [J]. Proc Natl Acad Sci USA, 1995, 92(20): 9082-9086.
  • 9Xu D, Gruber A, Peterson C, et al. Telomerase activity and the expression of telomerase compontent in acute myelogenous leukemia [J]. Br J Haematol,1998,102(5):1367-1375.
  • 10Hiyama E, Hiyama K. Clinical utility of telomerase in cancer [J]. Oncogene, 2002, 21(4):643-649.

二级参考文献6

  • 1[1]Kononen J, Bubendorf L, Kallioniemi A,et al. Tissue microarrays for high throughput molecular profiling of tumor specimen [J]. Nat Med, 1998,4(7):844-847.
  • 2[2]Belair CD, Yeager TR, Lopez PM, et al. Telomerase activity a biomarker of cell proliferation, not malignant transformation [J]. Proc Natl Acad Sci USA, 1997,94(25):13677-13682.
  • 3[3]Kenji N, Elizabeth W, James K,et al. Telomerase activity and expression of telomerase ENA component and telomerase catalytic subunit gene in cervical cancer [J]. AM J Pathol, 1998,153(3):857-864.
  • 4[4]Kazuo Y, Raheeia A, Jan N, et al. Telomerase activity and expression of its RNA component in cervical lesions [J]. Cancer,1998,82(7):1319-1327.
  • 5[5]Schraml P, Kononen J, BubendorfL, et al. Tissuemicroarrays for gene amplification surveys in many different tumor types [J]. Clin Cancer Res,1999,5(8):1966-1975.
  • 6[6]Richter J, Wagner U, Kononen J,et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer[J]. Am J Pathol,2000,157(3):787-794.

共引文献6

同被引文献9

  • 1李新明,张永福.口腔颌面部间叶组织恶性肿瘤细胞 DNA 含量的流式细胞分析[J].华西口腔医学杂志,1993,11(3):173-176. 被引量:3
  • 2霍雄伟,马清涌,许康铃,孙学军,刘浩,车向明,盛薇.甲状腺癌组织端粒酶逆转录酶和P53基因表达及其临床意义[J].西安交通大学学报(医学版),2004,25(5):453-455. 被引量:5
  • 3Yan P, Coindre JM, Benhattar J, et al. Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology,and proliferative activity. Cancer Res, 1999,59(13): 3166
  • 4Liu Y, Snow BE, Hande MP, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol, 2000,10(22) :1459
  • 5Koyanagi Y, Kobayashi D, Yajima T, et al. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemia cells. Anticancer Res, 2000, 20(2A): 773
  • 6Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science, 1998, 279(5 349) :349
  • 7Kim HR, Christensen R, Park NH, et al. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clinical Cancer Res, 2001, 7(10): 3079
  • 8Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene, 2002,21(4): 643
  • 9孔祥永,安靓,陶少华,陈玥,杜江,封志纯.人胎肺发育不同阶段端粒酶逆转录酶的表达及意义[J].第一军医大学学报,2004,24(5):566-568. 被引量:3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部